Haleon Regulatory News (HLN)

EMTN programme: publication of base prospectus

12 May 2023: Haleon plc (the "Company") (LSE/NYSE: HLN) today announces that the base prospectus regarding Haleon UK Capital plc's and Haleon Netherlands Capital B.V.'s £10,000,000,000 Euro Medium Term Note ("EMTN") Programme, guaranteed by the Company, has been published (the "Base Prospectus").

A copy of the Base Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at and can be downloaded from:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism

and

https://www.haleon.com/investors/debt-investors

Ends

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.

Disclaimer

Please note that the information contained in the Base Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Prospectus is not addressed. Prior to relying on the information contained in the Base Prospectus, you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained in the Base Prospectus.

Your right to access this service is conditional upon complying with the above requirement.